Cartesian Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company is headquartered in Frederick, Maryland and currently employs 66 full-time employees. The company went IPO on 2016-06-22. The company leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function. The Company’s lead asset, Descartes-08, is a chimeric antigen receptor T-cell therapy (CAR-T) entering Phase 3 clinical development for patients with generalized myasthenia gravis and Phase 2 development for systemic lupus erythematosus, with a Phase 2 basket trial planned in additional autoimmune indications. The Company’s clinical-stage pipeline also includes Descartes-15, a next-generation, autologous anti-B-cell maturation antigen (BCMA) CAR-T being evaluated in a Phase 1 trial in patients with multiple myeloma. Descartes-08 is an autologous chimeric antigen receptor T-cell therapy product targeting B-cell maturation antigen in clinical development for generalized myasthenia gravis and systemic lupus erythematosus.
Follow-Up Questions
Who is the CEO of Cartesian Therapeutics Inc?
Dr. Carsten Brunn is the President of Cartesian Therapeutics Inc, joining the firm since 2018.
What is the price performance of RNAC stock?
The current price of RNAC is $9.3, it has increased 3.27% in the last trading day.
What are the primary business themes or industries for Cartesian Therapeutics Inc?
Cartesian Therapeutics Inc belongs to Biotechnology industry and the sector is Health Care
What is Cartesian Therapeutics Inc market cap?
Cartesian Therapeutics Inc's current market cap is $241.9M
Is Cartesian Therapeutics Inc a buy, sell, or hold?
According to wall street analysts, 9 analysts have made analyst ratings for Cartesian Therapeutics Inc, including 5 strong buy, 7 buy, 3 hold, 0 sell, and 5 strong sell
